SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 9/21/2017 2:19:19 PM - Followers: 193 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine 09/19/2017 09:00:00 AM
CVM News: CEL-SCI to Present Today at the 19th Annual Rodman & Renshaw Global Investment Conference 09/11/2017 09:00:00 AM
CVM News: Notice of Effectiveness (effect) 09/05/2017 06:02:31 AM
CVM News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 08/31/2017 05:31:58 PM
CVM News: Current Report Filing (8-k) 08/31/2017 05:19:22 PM
PostSubject
#8718  Sticky Note Do with this information what you will,... I drkazmd65 09/26/16 01:49:06 PM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#12064   Interesting.... head and neck, hpv... https://www.eurekalert.org/pub_releases/ trickledownfacists 09/21/17 02:19:19 PM
#12063   An established appropriation of funds via grant. learning curve 09/21/17 03:32:05 AM
#12062   Tell everybody to read a 10q. learning curve 09/21/17 03:27:08 AM
#12061   Ask away? What is puzzling? learning curve 09/21/17 03:24:05 AM
#12060   Affirm trickledownfacists 09/20/17 11:32:26 AM
#12059   9/19/2017 8:22:10 AM VIENNA, Va.--(BUSINESS WIRE)--CEL Foxwoods Man 09/20/17 11:31:13 AM
#12058   There was a grant years ago. yankeesnyc27 09/20/17 11:30:03 AM
#12057   The original grant a year ago I believe trickledownfacists 09/20/17 11:23:48 AM
#12056   What is the date of the $1.5 M ? yankeesnyc27 09/20/17 11:03:01 AM
#12055   Agree Derf11 09/20/17 10:13:15 AM
#12054   Learning Curve sea alice 09/20/17 08:37:22 AM
#12053   CEL-SCI Announces $1.5 Million NIH SBIR Grant to trickledownfacists 09/19/17 09:25:58 AM
#12052   The individual whom is brilliant and mutilpes more learning curve 09/19/17 03:00:19 AM
#12051   In addition to previous post.... learning curve 09/19/17 02:50:31 AM
#12050   So can somebody who likes trading lines tell learning curve 09/19/17 02:43:53 AM
#12049   http://www.marketwatch.com/story/cancer-vaccines-long-considered-failures-are-ho trickledownfacists 09/17/17 10:35:39 AM
#12048   Waiting on Arb. The one year anniversary for trickledownfacists 09/16/17 09:20:36 AM
#12047   I'm still stuck on why I can see learning curve 09/16/17 01:32:23 AM
#12046   Somebody help me out on this, I seem lightrock 09/14/17 07:56:04 PM
#12045   Adds more credibility to his $500k investment. Trustbaby 09/13/17 06:41:51 PM
#12044   Double affirm Foxwoods Man 09/13/17 06:17:18 PM
#12043   Affirm trickledownfacists 09/13/17 05:59:25 PM
#12042   Listening to Geert's presentation, it became clear to JakeJ 09/13/17 05:41:14 PM
#12041   Nothing new came out of the seminar except trickledownfacists 09/13/17 12:08:36 PM
#12040   My meaning was; why there was nobody posting Turney 09/13/17 12:02:39 PM
#12039   What is there to be pissed about? Trustbaby 09/13/17 09:53:47 AM
#12038   No. Waiting for a surprise or a realistic .50? learning curve 09/13/17 03:07:48 AM
#12037   Is everybody pissed off? Turney 09/12/17 08:27:11 PM
#12036   CAO also unloads 42K shares valued at 2.5 sinity 09/09/17 09:47:30 AM
#12035   Thank you for sharing!!!! sinity 09/08/17 11:21:17 AM
#12034   That would be hysterical if there's a connection Trustbaby 09/08/17 09:57:00 AM
#12033   Now the CFO of INC Research sells 50% trickledownfacists 09/08/17 09:26:02 AM
#12032   RHETORICAL? The post was NOT rhetorical , It was yankeesnyc27 09/08/17 12:37:33 AM
#12031   Everybody here is probably in the top 10. learning curve 09/07/17 10:49:26 PM
#12030   Wasn't responding to you. trickledownfacists 09/07/17 02:41:36 PM
#12029   So sorry 'bout caps didn't mean to. I Turney 09/07/17 02:24:31 PM
#12028   It would be great if you would add trickledownfacists 09/07/17 01:38:05 PM
#12027   You better hope so. Question, if you can't Turney 09/07/17 01:26:47 PM
#12026   INC research "inVentiv" chief Admin officer sells about trickledownfacists 09/07/17 09:49:33 AM
#12025   its obvious I have not clue, really? warfaretrader 09/07/17 08:52:59 AM
#12024   So Denny Sanford invited me for a quick chat... learning curve 09/07/17 03:48:04 AM
#12023   What kinda nut shell is that!?? learning curve 09/07/17 03:36:23 AM
#12022   I'm not on the other end of any learning curve 09/07/17 03:13:25 AM
#12021   Cmon now. They can always sell more non learning curve 09/07/17 03:02:59 AM
#12020   WHO ARE THE DEBT HOLDERS? yankeesnyc27 09/07/17 01:15:43 AM
#12019   My biggest fear is we shareholders get gutted Turney 09/06/17 01:57:22 PM
#12018   Fortunately we have a few things in favor Trustbaby 09/06/17 09:19:33 AM
#12017   Agreed trickledownfacists 09/05/17 11:07:27 PM
#12016   Yep - Definitely it's going to be one drkazmd65 09/05/17 09:45:05 PM
#12015   sorry, I'm not giddy or excited about the warfaretrader 09/05/17 09:12:56 PM
PostSubject